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doi:10.1016/j.fjs.2011.08.006Summary Osteonecrosis of the femoral head (ONFH) has had a great socioeconomic impact
on Asian populations. The etiology of the disease is not fully understood. Corticosteroid use is
the most firmly established risk factor. Recent studies have pointed out the genetic basis of
nontraumatic ONFH. The common fate of various contributing factors is microcirculation
disturbance. In general, the treatment for early-stage ONFH is core decompression surgery
with adjuvant measures such as various types of bone grafts. Hip replacement, either hemiar-
throplasty or total hip replacement, can lead to good results. Recent studies have shed some
light on non-operative treatments for early-stage disease, although long-term results are still
lacking. The modes of treatment include shock wave therapy and oral administration of bi-
sphosphonate, vitamin E, and vitamin K2. Advances in tissue engineering may make biological
joint replacement possible in the near future.
Copyright ª 2011, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Osteonecrosis of the femoral head (ONFH) is a pathologic
condition of the hip joint that was previously referred to as
avascular necrosis (AVN). Disruption of the blood supply toaumatology, Taipei Veterans
Shih-Pai Road, Taipei 112,
ov.tw.
ight ª 2011, Taiwan Surgical Assothe femoral head is commonly believed to cause bone
necrosis and further hip joint destruction. As early as 1738,
Munro first described a case of ONFH. Over 200 years later,
Mankin reported on a series of 27 cases and named the
disease AVN.1 This brought the disease to the attention of
orthopedic specialists and the literature on ONFH has been
increasing since.
The socioeconomic impact of ONFH on society cannot be
overemphasized. In the USA, ONFH accounts for 5e18% of
total hip replacement (THR) surgeries annually.2 Among the
Asian population, ONFH plays a much more important role.ciation. Published by Elsevier Taiwan LLC. All rights reserved.
132 W.-M. ChenIn Taiwan, 46.3% of all THR surgeries are for ONFH.3 The
literature shows a high prevalence of the disease in Japan
and Korea4,5 compared to Caucasian populations. A case
series of 647 hips in Hong Kong revealed that ONFH
accounted for 45.6% of all hip replacements.6 These data
indicate that the disease is more prevalent in Asia and
hence has been studied more thoroughly by Asian scientists
and surgeons.
2. Etiology
Despite the general belief that ONFH stems from insuffi-
cient blood supply to the femoral head, the reason for such
circulation disruption remains to be explored. ONFH can be
categorized into three groups: trauma-associated ONFH, in
which vessels supplying the femur head are torn during
a traumatic event7,8; ONFH associated with known risk
factors; and idiopathic ONFH. Known risk factors for ONFH
include corticosteroid use, alcohol abuse, and coagulo-
pathies such as Gaucher’s disease, renal failure, and
protein C/protein S deficiency. Corticosteroid use is ranked
top for all possible etiologies. Approximately 5e25% of
those who received intensive corticosteroid therapy (over 1
month) could develop ONFH.9,10
Numerous articles in the literature have revealed that
many cases previously thought to be idiopathic ONFH were
in fact related to genetic traits. Miyamoto et al reported
that a recurrent mutation in the type II collagen gene
caused pediatric ONFH (LeggeCalveePerthes disease) in
a Japanese family.11 Liu et al discovered the gene respon-
sible for hereditary primary ONFH in Taiwan.12 Glueck
et al13 and Jones et al14 also reported that heritable
thrombophilia or hypofibrinolysis is often present in
Western countries.
Regardless of the proposed etiology, current evidence
tends to support the hypothesis that the common prelude
to ONFH is microvascular thrombosis (Figure 1). Long-term
intensive corticosteroid therapy or alcohol abuse can lead
to the formation of fat emboli. Mutations in various genes,
such as hypoxia-inducible factor 1-alpha,15 NO synthase,16
and factor V Leiden,17 lead to microvascular disturbance.Figure 1 Etiology of osteonecrosis of the femoral head. The
common pathway involves disruption of the microvascular
circulation and subsequent ischemia at the femoral head.According to these new findings, it is now more likely that
ONFH is a common consequence of various disease entities.
3. Disease staging and diagnosis
The most popular staging system for ONFH is the Ficat
system.18 In Stage I disease, the patient has ONFH but plain
radiographs show no abnormality. Stage II disease involves
an osteonecrotic lesion with either higher radio-opaque
density or a cystic appearance. The shape of the femoral
head remains intact without collapse. When the disease
progresses further to Stage III, there is osteochondral
fracture of the femoral head which leads to the typical
crescent appearance on plain radiographs. In Stage IV
disease, there are secondary osteoarthritic changes in both
the femoral head and the acetabulum. Many other staging
or classification systems exist, but most of those are
modifications of the original Ficat system.
The strategy for ONFH diagnosis is much the same as for
other orthopedic pathologies. These include taking the
patient’s medical and family history, a physical examina-
tion, and subsequent imaging studies as indicated. A
differential diagnosis is warranted if the patient has
a medical history of corticosteroid therapy, alcohol abuse,
or a family history of ONFH. As the disease progresses, the
patient may present with a limping gait due to severe pain
in the hip joint. A Patrick test should reveal positive signs
(i.e., pain in the groin area). Plain radiographs remain the
first-line screening tool. If these show no bone abnormality
but ONFH is highly suspected, magnetic resonance imaging
(MRI) is indicated. It has been demonstrated that MRI is the
most sensitive and specific imaging modality for diagnosis
of Stage I ONFH.19 Scintigraphy is less sensitive and specific
in detecting early-stage disease. Currently, scintigraphy
can be performed on high-risk patients to delineate multi-
focal lesions in addition to femoral head lesions.
4. Non-surgical treatment
Over the past decades, efforts to search for non-surgical
cures for ONFH have been ceaseless. Although a few reports
have proposed the possibility of spontaneous resolution of
early stage ONFH, current evidence indicates that without
proper treatment, early-stage disease will inevitably prog-
ress to femoral head collapse in most cases.20
Lai et al21 and Agarwala et al22 reported possible bene-
fits of bisphosphonates. In the study by Lai et al, only two of
29 femoral heads collapsed in the patients treated with
alendronate, while 19 of 25 femoral heads collapsed in
those without alendronate use. In an animal model, vitamin
E was proposed to potentially prevent steroid-induced
osteonecrosis due to its anticoagulant nature.23 It has
been reported that certain Chinese drugs enhance angio-
genesis through VEGF gene transfer.24 Wang et al compared
two groups of patients with Stage I, II or III disease treated
with extracorporeal shock waves or core decompression
with nonvascularized bone grafting. The short-term follow-
up results showed a better Harris hip score, pain relief and
lesion regression in patients with early-stage disease in the
shock wave group.25 Ludwig et al26 and Alves et al27 also
reported that high-energy shockwaves were beneficial.
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for cases in the early stage or the precollapse stage.
Definitive results for long-term follow-up are still
unavailable.
5. Surgical treatment
5.1. Early stage (Stages I and II)
For early-stage disease, core decompression is the mainstay
of surgical treatment. After drilling a tunnel into the target
part in the femoral head, the necrotic bone is removed and
the circulation is rebuilt. Based on an animal model, Wang
et al reported that core decompression may normalize
femoral head circulation that has been compromised by
methylprednisolone use.28 In 1996, Mont et al reported
good results compared with nonsurgical treatment for
early-stage disease,29 and in 2006 further confirmed the
value of such a procedure after reviewing studies by other
authors.30 In the 1980s, core decompression was questioned
as a dangerous and ineffective procedure.31 A large amount
of clinical evidence has since pointed to its safety and
effectiveness, and there is now a consensus on this treat-
ment for early-stage ONFH in developed countries.
In addition to simple decompression of the femoral
head, a number of adjuvant measures can enhance bone
healing. These include stem cell or bone morphogenic
protein (BMP) injection,32 tantalum rod insertion,33 bone
cement filling and bone grafting. The use of a tantalum rod
may strengthen the mechanical structure of the head, but
it may become troublesome in subsequent hip replace-
ment. Stem cells and BMPs provide two key components of
tissue engineering, but the critical third componentda
scaffold to assure efficacydis lacking. In 2009, a report
from France claimed that cementing the femoral head
leads to early pain relief,34 but no similar results have yet
been widely reproduced by others.
Bone grafting may be the most popular adjuvant at
present. Autogenous bone grafts, including vascularized or
nonvascularized, cancellous or strut (fibula), have all been
reported, with various results.35 In 2009, Chen et al
proposed an autogenous bone grafting technique.36 In this
approach, the same small surgical incision as for core
decompression is made and cancellous bone is taken from
the trochanteric area along the drilling tract and thenFigure 2 (A) Autogenous bone grafting technique proposed by
autogenous bone grafting material was harvested from the trocha
material was then impacted into the lesion site.impactedinto the target site (Figure 2). The series showed
better results compared with core decompression alone.
Sugioka’s osteotomy, a rotational osteotomy of the
proximal femur, is based on “turning” the good side of the
head to take the burden of weight bearing.37,38 In 2009,
Atsumi et al reported a modified procedure of the original
osteotomy with a high degree rotation to improve the
clinical result.39 Studies carried out by European and
American surgeons, however, all revealed an inferior
outcome. The divergence in outcomes between Japanese
and Western series remains to be investigated.
5.2. Late stage (Stages III and IV)
The consensus on treatment for Stage IV ONFH is THR. For
Stage III disease, the trend is also moving toward THR in
most developed countries. However, many still believe that
bipolar hemiarthroplasty plays a role.
5.2.1. Total hip arthroplasty
The current hot issue concerning THR is the bearing
system.40 Metal on polyethylene (PE) was the first widely
accepted bearing surface to provide reliable longevity.
Ceramic-on-ceramic systems have been used largely for
young active patients owing to their low wear rates. With
advances in modern materials engineering, new metal-on-
metal surfaces with low wear rates and minimal osteolysis
problems are expected in the future. At present, alternative
bearing couples including ceramic on highly crosslinked PE
and the above-mentioned bearings are gaining in popularity
because the mean age of ONFH patients receiving THR is less
than that of patients with primary osteoarthritis.41
Some have questioned the longevity of THR in ONFH
patients. In a retrospective comparative study by Lee,42
12,466 THRs (ONFH group) and 18,515 THRs (primary oste-
oarthritis) showed a comparable 8-year survival rate, which
was over 98% in both groups.
5.2.2. Bipolar hemiarthroplasty
The success rate for bipolar hemiarthroplasty in ONFH
patients is variable. Amstutz et al,43 Grevitt and Spencer44
and Chan and Shih45 reported satisfactory outcomes. They
also emphasized the advantage compared to THR: hemi-
arthroplasty preserves more bone stock for young patients
with a healthy acetabulum. Conversely, those against
hemiarthroplasty argue that the procedure is associatedChen et al. Core decompression was carried out. (B) The
nteric area using the same surgical wound. (C)The harvested
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problems.46,47 In a series reviewed by Lee, the 8-year
survival rate for 7407 bipolar hemiarthroplasties was not
different from that for 12,466 THRs with a revision for any
reason as the primary end point.47 While it seems that most
reports in the Western literature advocate THR for ONFH
patients, the large series in Taiwan provides a reminder
that bipolar hemiarthroplasty remains an option (Figure 3).
5.2.3. Other procedures
In 2003, Adili and Trousdale from the Mayo Clinic published
results on resurfacing hemiarthroplasty for ONFH.48 The
procedure was designed as a time-buying surgery for bone
stock preservation in young active patients. The survival
rate at 3 years was 75.9% in their series. Sharma and Cheng
reported a 4-year survival rate of 72.6% in 2007.49 The
indications for such a procedure are limited. The patient
should be young, generally less than 30 years of age. The
size of the femur should be large enough to support the
implant. The effect of pain relief is unpredictable. Finally,
the patient should fully understand that revision to THR is
nearly inevitable.
6. Future prospects
Advances in basic research have brought hope for ONFH
treatment. If technically possible, intervention can be
made before the disease attacks. This may be achieved by
avoiding risk factors for those with genetic problems, and
modification of genes or translated proteins. The 1990s was
the era heralding gene therapy, and now we are in the 21st
century, the so-called age of regenerative medicine. Since
gene manipulation has not yielded great success, regener-
ative medicine is emerging as the future hope for ONFHFigure 3 Plain radiograph of an ONFH patient who had left
THR and right hemiarthroplasty. After 11 years, both implants
were still surviving well and showing a comparable functional
outcome.patients. A great deal of such research is under way. Tissue
engineering of cartilage or bone could be used for biological
reconstruction of destroyed joint structures.50 There is still
a long way to go before clinical application, yet the dream
of biological joint replacement may be realized sooner than
expected.
7. Summary
ONFH has had a tremendous socioeconomic impact on the
population of Taiwan and is the reason for nearly half of
THR operations carried out annually. MRI is the best
modality in detection of early-stage disease. A surgical
approach remains the mainstay of treatment. For early-
stage disease, core decompression may save the femoral
head by rebuilding its microcirculation. Adjuvant proce-
dures such as autogenous bone grafting improve the success
rate. For late-stage disease, THR is the treatment of
choice. Currently, alternative bearing couples are
increasing in popularity because patients with ONFH are
generally younger than those with other diseases. For those
with an intact acetabulum, bipolar hemiarthroplasty may
lead to comparable results. Studies since the 1990s have
shed light on ONFH etiology. Various gene mutations have
been identified as the cause of microvascular thrombosis.
The trend is moving towards regenerative medicine. With
advances in tissue engineering, biological joint arthroplasty
may be feasible in the near future.
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